Management of Patients with Aggressive Pituitary Tumours

Chair Gerard Raverot, France

In July 2015, an ESE Special interest Group was established to propose a definition of aggressive pituitary tumours, develop guidance on therapeutic indication of temozolomide treatment for aggressive pituitary tumours and to evaluate the results of alternative clinical therapies on these tumours.

The SIG carried out a Europe-wide survey of specialists treating patients with aggressive pituitary tumours, asking questions about treatment courses and patient outcomes.

Following the analysis of this survey, a comprehensive literature review was carried out to develop the ESE Clinical Practice Guideline on the Management of Patients with Aggressive Pituitary Tumours, which was present during the European Congress of Endocrinology in 2017 in Lisbon.

Recommendations for treatment to be presented at ECE 2017 and published in EJE

Subscribe to our email alerts